FDA Approved: AFINITOR DISPERZ — Original Application (Novartis Pharmaceuticals Corporation)

View source ↗

Summary

FDA approves AFINITOR DISPERZ (everolimus) under an Original Application for a dispersible tablet formulation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Neuroendocrine Tumor
• Renal Cell Carcinoma
• Tuberous Sclerosis Complex-associated Renal Angiomyolipoma
• Tuberous Sclerosis Complex-associated Subependymal Giant Cell Astrocytoma

Drugs mentioned

• AFINITOR DISPERZ (everolimus)

Snippet

ORIG AP for AFINITOR DISPERZ (EVEROLIMUS)